Shares of IMMUNEONCO-B (01541) jumped nearly 12% during Tuesday trading, last up 10.41% at HK$4.085 with turnover reaching HK$3.429 million.

The surge follows the company's interim results released on the evening of August 26. For the first half of 2026, the biotech firm reported revenue of RMB 25.424 million, primarily derived from payments received under its licensing and collaboration agreement with Axion Bio.

The company maintains a robust cash position. As of June 30, 2026, its combined holdings of cash and cash equivalents, financial assets measured at fair value, and time deposits with original maturities exceeding three months totaled approximately RMB 947 million.

During the reporting period, the company continued to rapidly advance its drug pipeline, achieving significant milestones and accomplishments in both tumor immunotherapy and autoimmune disease areas.

Major clinical-stage assets, including IMM01 (Tidapacsip), IMM0306 (Amurefupr alfa), and IMM2510 (Perweilafupr alfa), made substantial progress, with several key clinical trials reaching critical junctures.

Meanwhile, the company is actively expanding beyond oncology into non-tumor treatment fields, making notable strides in autoimmune diseases, metabolic disorders, cardiovascular conditions, and pulmonary arterial hypertension, further unlocking the therapeutic potential of its drug candidates.